Progress in pharmacotherapy of pulmonary arterial hypertension in children / 中国当代儿科杂志
Chinese Journal of Contemporary Pediatrics
;
(12): 236-240, 2012.
Artigo
em Chinês
| WPRIM
| ID: wpr-320675
ABSTRACT
This paper provides an overview of the current state of pharmacotherapy in children with pulmonary arterial hypertension (PAH) and a brief introduction to the potentially novel pharmacologic targets for PAH. Currently, 3 classes of drugs including prostacyclin analogues, endothelin receptor antagonists and phosphodiesterase-5 inhibitors are approved for the treatment of PAH in children, which has led to improved hemodynamics, increased exercise capacity and prolonged survival. Despite these improvements, there is still a need to carry out well-designed, randomized, controlled studies with larger samples. In addition, novel drugs targeting other molecular pathways should be developed.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Sulfonamidas
/
Bloqueadores dos Canais de Cálcio
/
Iloprosta
/
Epoprostenol
/
1-(5-Isoquinolinasulfonil)-2-Metilpiperazina
/
Usos Terapêuticos
/
Diagnóstico
/
Tratamento Farmacológico
/
Hipertensão Pulmonar Primária Familiar
/
Hipertensão Pulmonar
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo diagnóstico
Limite:
Criança
/
Humanos
Idioma:
Chinês
Revista:
Chinese Journal of Contemporary Pediatrics
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS